Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
47.41
+0.25 (0.53%)
Dec 15, 2025, 3:10 PM EST - Market open
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $192.10M in the quarter ending September 30, 2025, with 9.34% growth. This brings the company's revenue in the last twelve months to $661.38M, up 1.44% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm)
$661.38M
Revenue Growth
+1.44%
P/S Ratio
3.87
Revenue / Employee
$1,011,185
Employees
674
Market Cap
2.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
| Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
| Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
| Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
| Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
| Dec 31, 2019 | 392.76M | -16.14M | -3.95% |
| Dec 31, 2018 | 408.90M | 106.66M | 35.29% |
| Dec 31, 2017 | 302.24M | 87.24M | 40.57% |
| Dec 31, 2016 | 215.00M | 67.54M | 45.80% |
| Dec 31, 2015 | 147.47M | 54.79M | 59.12% |
| Dec 31, 2014 | 92.68M | 80.66M | 671.10% |
| Dec 31, 2013 | 12.02M | 10.54M | 712.09% |
| Dec 31, 2012 | 1.48M | 677.00K | 84.31% |
| Dec 31, 2011 | 803.00K | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SUPN News
- 6 days ago - Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewsWire
- 23 days ago - Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 5 weeks ago - Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Supernus Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals: Heading In The Right Direction - Seeking Alpha